書籍詳細

1. レジン (陰イオン交換樹脂) の歴史

P.13 掲載の参考文献

• 1) Brown MS, Goldstein JL:A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47, 1986
  pubmed

• 2) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984
  pubmed

• 3) Baigent C et al:Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366:1267-1278, 2005
  pubmed

• 4) Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 148:36-69, 1988

• 5) Watanabe M et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006
  pubmed

2. 脂質の吸収メカニズム (主としてコレステロールについて)

P.21 掲載の参考文献

• 1) 今泉勝己ほか:大学食堂定食のリン脂質含量. 日本栄養・食糧学会誌 37:185-187, 1984
  Medical*Online

• 2) Carey MC, Hernell O:Digestion and absorption of fat. Semin Gastrointest Dis 3:189-208, 1992

• 3) Carey MC et al:Lipid digestion and absorption. Annu Rev Physiol 45:651-677, 1983
  pubmed

• 4) Duan R-D:Enzymatic aspects of fat digestion in the gastrointestinal tract. Ed. by Christophe AB, De Vriese S, "Fat Digestion and Absorption", AOCS Press, 2000, p25-46

• 5) Lowe ME:The triglyceride lipase of the pancreas. J Lipid Res 43:2007-2016, 2002
  pubmed

• 6) Yu L:The structure and function of Niemann-Pick C1-like protein. Curr Opin Lipidol 19:263-269, 2008

• 7) Hussain MM:A proposed model for the assembly of chylomicrons. Atherosclerosis 148:1-15, 2000
  pubmed

• 8) Neeli I et al:Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum. J Biol Chem 282:17974-17984, 2007
  pubmed

• 9) Yamaoka-Tojo M et al:Beyond cholesterol lowering:pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol 6:271-281, 2008
  pubmed

• 10) Matthan NR, Lichtenstein AH:Approaches to measuring cholesterol absorption in humans. Atherosclerosis 174:197-205, 2004
  pubmed

3. コレステロールの体内動態

P.27 掲載の参考文献

• 1) Sato R et al:Degradation of newly synthesized apolipoprotein B-100 in a pre-Golgi compartment. J Biol Chem 265:11880-11884, 1990

• 2) Wetterau JR et al:An MTP inhibitor that normalizes atherogenic lipoprotein levelos in WHHL rabbits. Science 282:751-754, 1998
  pubmed

• 3) Hirokane H et al:Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 279:45685-45692, 2004
  pubmed

• 4) Zelcer N et al:LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325:100-104, 2009
  pubmed

• 5) Tamehiro N et al:SREBP-and LXR-driven dual promoter regulation of hepatic ABCA1 gene expression:Mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 282:21090-21099, 2007
  pubmed

• 6) Agellon LB et al:Dietary cholesterol fails to stimulate the human cholesterol 7 α-hydroxylase gene (CYP7A1) in transgenic mice. J Biol Chem 277:20131-20134, 2002

• 7) Kanayama T et al:Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities. J Biol Chem 282:10290-10298, 2007
  pubmed

4. 脂質異常症治療におけるレジンの位置づけ (ガイドライン2007をふまえて)

P.32 掲載の参考文献

• 1) Scandinavian Simvastatin Survival Study Group:Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994

• 2) Okazaki S et al:Early statin treatment in patients with acute coronary syndrome:demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event:the ESTABLISH Study. Circulation 110:1061-1068, 2004
  pubmed

• 3) Edison RJ, Muenke M:Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350:1579-1582, 2004
  pubmed

5. レジンの効果とスタチンとの併用療法

P.37 掲載の参考文献

• 1) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251(3):365-374, 1984
  pubmed

• 2) Watts GF et al:Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339(8793):563-569, 1992

• 3) Suzuki T et al:Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia:a case-control study comparing colestimide with acarbose. J Nippon Med Sch 73(5):277-284, 2006
  pubmed

• 4) Kobayashi M et al:Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56(1):239-247, 2007
  pubmed

• 5) Strandberg TE et al:Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly:a prospective study. J Am Coll Cardiol 48(4):708-714, 2006
  pubmed

• 6) コレスチミド承認時臨床成績集計.

• 7) Kane JP et al:Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264(23):3007-3012, 1990
  pubmed

• 8) Kawashiri MA et al:Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 69(5):515-520, 2005
  pubmed

6. レジンの単独療法およびフィブラートとの併用療法

P.42 掲載の参考文献

• 1) Yamakawa T et al:Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 54(1):53-58, 2007
  pubmed

• 2) Suzuki T et al:Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia:acase-control study comparing colestimide with acarbose. J Nippon Med Sch 73(5):277-284, 2006

• 3) Kobayashi M et al:Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56(1):239-247, 2007
  pubmed

• 4) Baxter JD, Webb P:Metabolism:bile acids heat things up. Nature 439:402-403, 2006
  pubmed

• 5) Watanabe M et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006
  pubmed

• 6) 梶山梧朗ほか:新規陰イオン交換樹脂MCI-196のヒト胆汁脂質に与える影響について. 臨床医薬 12(7):1349-1359, 1996
  Medical*Online

7. レジンの副作用と対策 (特に便秘について)

P.48 掲載の参考文献

• 1) Dowling RH:The enterohepatic circulation. Gastroenterology 62:122-140, 1972
  pubmed

• 2) Shepherd J:Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 76:65-74, 1989
  pubmed

• 3) 松橋有紀ほか:血中総コレステロール低下と便中総胆汁酸排泄のコレスチミド用量依存性について. 消化と吸収 27:16-19, 2004

• 4) Nakamura T et al:Faecal lipid excretion levels in normal Japanese females on an unstricted diet and a fat-restricted diet measured by simultaneous analysis of faecal lipids. J Int Med Res 20:461-466, 1992

• 5) Mitchell WD et al:Bile acids in the diarrhea of ileal resection. Gut 14:348-353, 1973
  pubmed

• 6) Corazza GR et al:Cyclic AMP and cyclic GMP levels in human colonic mucosa before and during chenodeoxycholic acid therapy. Gut 20:489-492, 1979
  pubmed

• 7) 武藤泰敏, 冲中重雄:4. 消化・吸収の生理(I):消化・吸収-消化管機能の調節と適応-. 第一出版, 1976, pp101-170

• 8) 秦真奈美ほか:高コレステロール血症治療薬コレバイン (コレスチミド製剤) の使用成績調査. 新薬と臨床 57:754-773, 2008
  Medical*Online

• 9) 片本哲郎:便秘症の日常生活指導. 診断と治療 89:438-439, 2001
  Medical*Online

• 10) Matsuzaka M et al:Bowel habits in the Japanese population. J Phys Fit Nutr Immunol 13:9-16, 2003

• 11) 長谷川範幸ほか:短腸症候群に対してコレスチミド, ポリカルボフィルカルシウム投与が有効であった一例. 消化と吸収 30:5-7, 2007

8. 大規模臨床試験LRC-CPPT

P.55 掲載の参考文献

• 1) Lipid Research Clinics Program:The lipid Research Clinics Coronary Primary Prevention Trial Results. I, Reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984

• 2) Lipid Research Clinics Program:The lipid Research Clinics Coronary Primary Prevention Trial Results. II, The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984

• 3) Report from The Committee of Principal Investigators:A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069-1118, 1978

• 4) Report from The Committee of Principal Investigators WHO Cooperative Trial on Primary Prevention of Ischaemic Heart Disease with Clofibrate to Lower Serum Cholesterol:Final mortality follow-up. Lancet 2:600-604, 1984

• 5) The Lipid Research Clinics Program:The Coronary Primary Prevention Trial:Design and implementation. J Chronic Dis 32:609-631, 1979
  pubmed

• 6) The Coronary Drug Project Research Group:Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975

• 7) Shepherd J et al:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995
  pubmed

• 8) West of Scotland Coronary Prevention Study Group:Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445, 1998

• 9) Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. Arch Intern Med 152:1399-1410, 1992
  pubmed

• 10) Strandberg TE et al for the 4S group:Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771-777, 2004
  pubmed

• 11) Scandinavian Simvastatin Survival Study Group:Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease:Scandinavian Simvastatin Survival Study(4S). Lancet 344:1383-1389, 1994

9. エネルギー代謝における胆汁酸の働きとレジンの位置づけ

P.63 掲載の参考文献

• 1) Houten SM et al:Endocrine functions of bile acids. Embo J 25:1419-1425, 2006
  pubmed

• 2) Watanabe M et al:Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113:1408-1418, 2004

• 3) Watanabe M et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006
  pubmed

• 4) Baxter JD et al:Selective activation of thyroid hormone signaling pathways by GC-1:a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 15:154-157, 2004
  pubmed

• 5) Virtanen KA et al:Functional brown adipose tissue in healthy adults. N Engl J Med 360:1518-1525, 2009
  pubmed

• 6) van Marken Lichtenbelt WD et al:Cold-activated brown adipose tissue in healthy men. N EnglJMed 360:1500-1508, 2009

• 7) Kobayashi M et al:Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56:239-247, 2007
  pubmed

• 8) Suzuki T et al:Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia:a case-control study comparing colestimide with acarbose. J Nippon Med Sch 73:277-284, 2006
  pubmed

• 9) Yamakawa T et al:Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 54:53-58, 2007
  pubmed

• 10) Zieve FJ et al:Results of the glucose-lowering effect of WelChol study(GLOWS):a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29:74-83, 2007
  pubmed

10. レジンの幅広い使い方

P.70 掲載の参考文献

• 1) Cariou B et al:Farnesoid X receptor:a new player in glucose metabolism? Endocrinology 146:981-983, 2005
  pubmed

• 2) Laffitte BA et al:Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419-5424, 2003
  pubmed

• 3) Zhang Y et al:Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103:1006-1011, 2006
  pubmed

• 4) Kawabata Y et al:Bile Acid Binding Resin Ameliorates Glycemic Control in Patients with Type 2 Diabetes. Diabetes 55 (suppl.):A120, 2006

• 5) Kobayashi M et al:Prevention and Treatment of Obesity, lnsulin Resistance, and Diabetes by Bile-Binding Resin. Diabetes 56:239-247, 2007

• 6) Watanabe M et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006
  pubmed

• 7) 日本糖尿病学会編集:14 糖尿病に合併した高脂血症. 科学的根拠に基づいた糖尿病診療ガイドライン改訂第2版, 南江堂, 東京, 2007, p171

• 8) Suzuki T et al:Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia:a case-control study comparing colestimide with acarbose. J Nippon Med Sch 73:277-284, 2006
  pubmed

• 9) Suzuki T et al:Effects of colestimide on blood glucose-lowering activity and body weight in patients with type 2 diabetes and hypercholesterolemia. J Nippon Med Sch 74:81-84, 2007
  pubmed

• 10) Yamakawa T et al:Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 54:53-58, 2007
  pubmed

• 11) Takebayashi K et al:Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 102(4):361-368, 2009
  pubmed

• 12) Bays HE et al:Colesevelam Hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med Diabetes 168:1975-1983, 2008
  pubmed

P.76 掲載の参考文献

• 1) The lipid Research Clinics Coronary Primar Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984

• 2) The lipid Research Clinics Coronary Primar Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351-364, 1984

• 3) MCI-196研究会:高コレステロール血症患者におけるMCI-196の有用性の検討. 臨床医薬 12(8):1641-1692, 1996
  Medical*Online

• 4) Watanabe M et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006
  pubmed

• 5) Kobayashi M et al:Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56:239-247, 2007
  pubmed

• 6) Zhang Y et al:Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103:1006-1011, 2006
  pubmed

• 7) Cao G et al:Antidiabetic action of a liver x receptor agonist mediated by inhibition of hepatic gluconeogenesis. J Biol Chem 278:1131-1136, 2003
  pubmed

• 8) Laffitte BA et al:Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419-5424, 2003
  pubmed

• 9) Watanabe M et al:Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113:1408-1418, 2004

• 10) Yamakawa T et al:Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 54:53-58, 2007
  pubmed

• 11) Zieve FJ et al:Results of the glucose-lowering effect of WelChol study(GLOWS):a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29:74-83, 2007
  pubmed

• 12) Goldberg R et al:Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy Arch Intern Med 168:1531-1540, 2008
  pubmed

P.83 掲載の参考文献

• 1) Yamada S et al:Waist circumference in metabolic syndrome. Lancet 370:1541-1542, 2007
  pubmed

• 2) Yamaoka-Tojo M et al:Effect of colestimide on reduction of body weight and waist circumference in metabolic syndrome patients with cardiovascular risk factors. Vascular Disease Prevention 5:183-189, 2008

• 3) 加藤大也ほか:メタボリックシンドロームを伴った脂質異常症を合併した糖尿病患者におけるコレスチミドの治療効果についての検討. Diabetes Frontier 18:693-696, 2007
  Medical*Online

• 4) Taniai M et al:Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol Res 39:685-693, 2009
  pubmed

• 5) Yamakawa T et al:Effect of colestimide therapy for glycemic control in type 2 diabetes with hypercholesterolemia. Endocr J 54:53-58, 2007
  pubmed

• 6) Takebayashi K et al:Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 102:361-368, 2009
  pubmed

• 7) Lipid research clinics program. The lipid research clinics coronary primary prevention trial results. JAMA 251:351-364, 1984

• 8) Garg A, Grundy SM:Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus:A short-term, double-blind, crossover trial. Ann Intern Med 121:416-422, 1994

• 9) Zieve FJ et al:Results of the Glucose-Lowering Effect of WelChol Study(GLOWS):A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 29:74-83, 2007
  pubmed

• 10) Bays HE et al:Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med 168:1975-1983, 2008
  pubmed

• 11) Sonnett TE et al:Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin Ther 31:245-259, 2009
  pubmed

P.88 掲載の参考文献

• 1) Yamaoka-Tojo M et al:Beyond cholesterol lowering:pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome. Curr Vasc Pharmacol 6(4):271-281, 2008
  pubmed

• 2) Lefebvre P et al:Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89(1):147-191, 2009
  pubmed

• 3) Yamakawa T et al:Effect of Colestimide Therapy for Glycemic Control in Type 2 Diabetes Mellitus with Hypercholesterolemia. Endocr J 54:53-58, 2007
  pubmed

• 4) Suzuki T et al:Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia:a case-control study comparing colestimide with acarbose. J Nippon Med Sch 73(5):277-284, 2006
  pubmed

• 5) Kobayashi M et al:Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56(1):239-247, 2007
  pubmed

• 6) Reasner CA:Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 52(2):136-144, 2008
  pubmed

• 7) Sakamoto S et al:Effects of colestimide and/or Bofu-tsusho-san on plasma and liver lipids in mice fed a high-fat diet. In Vivo 19(6):1029-1033, 2005
  pubmed

• 8) Sasaki H et al:Usefulness of preheparin lipoprotein lipase mass as a parameter for predicting the efficacy of colestimide. J Atheroscler Thromb 12(4):218-224, 2005
  pubmed

• 9) Yamaoka-Tojo M et al:Effect of colestimide on reduction of body weight and waist circumference in metabolic syndrome patients with cardiovascular risk factors. Vascular Disease Prevention 5(3):183-189, 2008

Topics :

P.94 掲載の参考文献

• 1) 環境省環境保健部環境リスク評価室:日本人におけるダイオキシン類の蓄積量について, ダイオキシン類の人への蓄積量調査(2002-2006), 2007. http://www.env.go.jp/

• 2) Kuratsune M et al(eds.):Yusho. Kyushu University Press, Fukuoka, 2004

• 3) Heilmann C et al:Reduced antibody responses to vaccinations in children exposed to PCBs. PLoS Med 3:1352-1359, 2006

• 4) Mocarelli P:Seveso:a teaching story. Chemosphere 43:391-402, 2001

• 5) Stewart PW et al:The relationship between prenatal PCB exposure and intelligence (IQ) in 9-year-old children. Environ Health Perspect 116:1416-1422, 2008
  pubmed

• 6) Ketchum NS et al:Serum dioxin and cancer in veterans of Operation Ranch Hand. Am J Epidemiol 149(7):630-639, 1999

• 7) Guo YL et al:Yucheng:health effects of prenatal exposure to polychlorinated biphenyls and dibenzofurans. Int Arch Occup Environ Health 77:153-158, 2004
  pubmed

• 8) Arsenescu V et al:Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. Environ Health Perspect 116:761-768, 2008
  pubmed

• 9) 森 千里:へその緒が語る体内汚染-未来世代を守るために. 知りたい! サイエンス29, 技術評論社, 東京, 2008

• 10) Fukata H et al:Necessity to measure PCBs and organochlorine pesticide concentrations in human umbilical cords for fetal exposure assessment. Eniviron Health Perspect 113:297-303, 2005
  pubmed

• 11) Kuratsune M et al(eds.):Yusho. Human Disaster Caused by PCBs and Related Compounds. Kyushu University Press, Fukuoka, pp268-313

• 12) Sakurai K et al:Pilot study to reduce dioxins in the human body. Intern Med 43:792-795, 2004
  pubmed

• 13) Sakurai K et al:Colestimide reduces blood polychlorinated biphenyl(PCB) levels. Intern Med 45:327-328, 2006
  pubmed

• 14) Mochida Y et al:Reduction of dioxins and polychlorinated biphenyls (PCBs) in human body. Hukuoka Acta Med (Fukuoka lgaku Zasshi) 98:106-113, 2007
  pubmed

• 15) Ishida T et al:The Accelerated Excretion of 2,3,4,7,8-Pentachlorodibenzofuran by Cholebine. Hukuoka Acta Med (Fukuoka Igaku Zasshi) 100:102-108, 2009

P.100 掲載の参考文献

• 1) Block GA et al:Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15(8):2208-2218, 2004
  pubmed

• 2) Nakai S et al:Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12:49-54, 2008
  pubmed

• 3) Clinical Practice Guideline for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42(3):S62-84, 2003

• 4) Date T et al:Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplants 18 Suppl 3:iii 90-93, 2003

• 5) Kurihara S et al:Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in haemodialysis patients:a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 20:424-430, 2005
  pubmed

• 6) Chertow GM et al:Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients. Kidney Int 62:245-252, 2002
  pubmed

• 7) Koiwa F et al:Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 9:340-346, 2002

• 8) Itoh K et al:Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. Ther Apher Dial 12:126-132, 2008
  pubmed